Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt

Sjogren's Syndrome: early-phase trial registry

7 of 21 indexed Sjogren's Syndrome trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #797 of 28,707 conditions by registered trial count.

21 US clinical trials · 7 currently recruiting · #797 of 28,707 conditions by registered trial count

Sjogren's Syndrome: 21 US clinical trials tracked, 7 recruiting.

Sjogren's Syndrome is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Dental and Craniofacial Research (NIDCR), running 6 of these trials.

Enrollment posture brief

Registry condition sjogrens-syndrome

OPEN 7 | RECR 33% | LATE 3 | EARLY 10 | RANK #797 | SPON 6

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Anal Cancer42.9%Sjogren's Syndrome (this)33%Allergic Conjunctivitis14.3%Attention Deficit Disorder W4.8%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Sjogren's Syndrome

Sjogren's Syndrome lists 7 open slots (33% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Sjogren's Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Sjogren's Syndrome is recruiting below its size-band peers.

    7 of 21 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Sjogren's Syndrome research.

    National Institute of Dental and Craniofacial Research (NIDCR) accounts for 6 of 21 trials (28.6%). 15 distinct sponsors appear on at least one study for this condition label.

  3. Typical Sjogren's Syndrome enrolment sits around 75 participants.

    Median target enrolment is 75 among the 21 trials that report a genuine target (sentinel values excluded). 11 of those (52.4%) plan for fewer than 100 participants.

  4. Sjogren's Syndrome research is mostly interventional.

    15 interventional and 6 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 25Phase 33

Open and recent trials

21 total, page 1 of 1

RECRUITING 1,150 participants

Characterization of Diseases With Salivary Gland Involvement

National Institute of Dental and Craniofacial Research (NIDCR)

NCT02327884

RECRUITING 1,000 participants

Maternal Autoimmune Disease Research Alliance (MADRA) Registry

Duke University

NCT03276923

RECRUITING 500 participants

Rheumatology Diet Study

University of Central Florida

NCT06339957

RECRUITING 300 participants

The Pathogenesis and Natural History of Sjogren's Disease

National Institute of Dental and Craniofacial Research (NIDCR)

NCT01425892

RECRUITING NA 200 participants

Creating Health Course Study for People With Rheumatological Conditions

Terry L. Wahls

NCT07180537

RECRUITING Phase 2 60 participants

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease

National Institute of Dental and Craniofacial Research (NIDCR)

NCT07281456

RECRUITING Phase 1 36 participants

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

Cullinan Therapeutics

NCT07041099

ACTIVE NOT RECRUITING Phase 3 655 participants

Nipocalimab in Moderate to Severe Sjogren's Disease

Janssen Research & Development

NCT06741969

ACTIVE NOT RECRUITING Phase 3 651 participants

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Amgen

NCT06104124

ACTIVE NOT RECRUITING Phase 3 612 participants

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

Novartis Pharmaceuticals

NCT05985915

ACTIVE NOT RECRUITING Phase 2 209 participants

A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

Amgen

NCT06312020

ACTIVE NOT RECRUITING Phase 1 23 participants

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

National Institute of Dental and Craniofacial Research (NIDCR)

NCT04496960

COMPLETED 100 participants

The Research Registry for Neonatal Lupus

NYU Langone Health

NCT00074373

COMPLETED Phase 2 75 participants

A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome

Hoffmann-La Roche

NCT02701985

COMPLETED NA 55 participants

TrueTear in Sjogren's Disease Patients

University of Pennsylvania

NCT03719885

COMPLETED Phase 2 30 participants

Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops

National Eye Institute (NEI)

NCT00001731

COMPLETED Phase 2 28 participants

Etanercept Therapy for Sjogren's Syndrome

National Institute of Dental and Craniofacial Research (NIDCR)

NCT00001954

COMPLETED 28 participants

Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome

National Institute of Dental and Craniofacial Research (NIDCR)

NCT00565526

COMPLETED Phase 1 24 participants

An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness

Parion Sciences

NCT01369589

COMPLETED Phase 1 17 participants

Omalizumab for Lupus

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NCT01716312

COMPLETED Phase 1 12 participants

Anti-CD20 Antibody Therapy for Sjogren's Syndrome

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00101829

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 5
Phase 3 3

Named interventions

Most-linked intervention names on Sjogren's Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
Placebo Other
2 trials
Cyclosporin A Drug
1 trials
RO5459072 Drug
1 trials
P-552 Drug
1 trials
TrueTear Intranasal Tear Neurostimulator Device
1 trials
Etanercept Drug
1 trials
No intervention; observational Other
1 trials

US sites by state

Facility locations filed on Sjogren's Syndrome trials. A trial with sites in several states counts in each.

Maryland 10 trials
Florida 6 trials
North Carolina 5 trials
California 5 trials
Pennsylvania 4 trials
New York 4 trials
Massachusetts 4 trials
Georgia 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Sjogren's Syndrome page

21 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sjogren's Syndrome condition card totals 21 registered trials; most-linked intervention Placebo; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.